Boston Scientific stock faces a weaker 2026 growth outlook
Published on 09/24/2026 at 15:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock was trading at USD 44.61 on the NYSE at 9:42 a.m. ET on September 24, 2026, down 0.02 percent from the previous close. The medical device maker is absorbing a weaker 2026 growth outlook, while its second-quarter figures remained above consensus estimates.
Growth outlook loses momentum
Zacks reported on September 24, 2026, that Boston Scientific's 2027 growth outlook is muted, with new catalysts expected to support results in 2028. That timeline shifts the investment debate from immediate acceleration toward execution through the next product cycle.
The company entered this period with a mixed operating signal. Growth expectations have weakened, but the second-quarter revenue result still showed expansion across the business, leaving the stock tied to the pace of recovery in its slower franchises.
Q2 revenue rises 7.5 percent
Boston Scientific generated USD 5.44 billion in second-quarter 2026 revenue, an increase of 7.5 percent from the same quarter a year earlier. Adjusted EPS reached USD 0.86, up 14.7 percent year over year and 3.6 percent above the consensus estimate, according to Zacks.
The comparison matters because Boston Scientific delivered faster earnings growth than revenue growth in Q2 2026. That spread points to operating leverage, although the weaker annual outlook places greater weight on whether new products can offset pressure in established franchises.
Stock trades near USD 45
At the September 24, 2026 intraday snapshot, Boston Scientific had a market capitalization of USD 66,306,519,600 and traded at USD 44.61, with the session change at minus 0.02 percent. The market is therefore assigning substantial value to the company's device portfolio while pricing in slower near-term growth.
For investors, the key tension is visible in the numbers: Q2 revenue increased 7.5 percent and adjusted EPS rose 14.7 percent, yet the longer growth path now extends toward 2028. The next valuation signal will come from whether reported growth can keep exceeding the reduced outlook.
Boston Scientific snapshot
- Company: Boston Scientific Corporation
- Ticker: BSX
- Trading venue: NYSE
- Price: USD 44.61 at 9:42 a.m. ET on September 24, 2026
- Market capitalization: USD 66,306,519,600 as of September 24, 2026
- Sector / Industry: Healthcare / Medical Devices
